(Q37687871)

22 August 2017

1 reference

title

The pharmacoeconomics of biologic therapy for IBD. (English)

1 reference

22 August 2017

Russell D Cohen

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Nature Reviews Gastroenterology & Hepatology

22 August 2017

published in

1 reference

22 August 2017

volume

7

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

103-109

1 reference

The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Geographic variation in the incidence of and mortality from inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Occupational distribution of inflammatory bowel disease among German employees

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Prognosis and quality of life in patients with ulcerative colitis and Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Prognosis in Crohn's disease--based on results from a regional patient group from the county of Copenhagen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Survival and causes of death in patients with inflammatory bowel disease: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Frequency of glucocorticoid resistance and dependency in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Recurrence after surgery in Crohn's disease. Relationship to location of disease (clinical pattern) and surgical indication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Infliximab prevents Crohn's disease recurrence after ileal resection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Advances in the management of Crohn's disease: economic and clinical potential of infliximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Annual cost of care for Crohn's disease: a payor perspective.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

The cost of hospitalization in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Inflammatory bowel diseases: health care and costs in Sweden in 1994

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

The costs of Crohn's disease in the United States and other Western countries: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Infliximab decreases resource use among patients with Crohn's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Infliximab use in Crohn's disease: impact on health care resources in the UK.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Infliximab maintenance therapy for fistulizing Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Economic implications of biological therapies for Crohn's disease: review of infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Cost-utility of initial medical management for Crohn's disease perianal fistulae.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Cost utility of initial medical management for Crohn's disease perianal fistula

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Management for severe Crohn's disease: a lifetime cost-utility analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Funding the new biologics--what can we learn from infliximab? The CCOHTA report: a gastroenterologist's viewpoint

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Funding the new biologics--a health economic critique of the CCOHTA report: infliximab for the treatment of Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Funding the new biologics--public policy issues in drug formulary decision making

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Morbidity of juvenile onset inflammatory bowel disease: effects on education and employment in early adult life.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Disability from inflammatory bowel disease among employees in West Germany

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Unemployment and disability in patients with moderately to severely active Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.232

Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease

31 March 2020

1 reference

12 December 2020

Epidemiology, course and socio-economic influence of inflammatory bowel disease

1 reference

12 December 2020

Inflammatory bowel disease: medical cost algorithms

1 reference

12 December 2020

Inflammatory bowel disease: costs-of-illness

1 reference

12 December 2020

Predictability of the postoperative course of Crohn's disease

1 reference

12 December 2020

Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients

1 reference

12 December 2020

10.1038/NRGASTRO.2009.232

Identifiers

DOI

1 reference

22 August 2017

1 reference